MARKET

SION

SION

Sionna Therapeutics
NASDAQ
12.90
+0.58
+4.71%
After Hours: 12.90 0 0.00% 16:00 05/12 EDT
OPEN
12.45
PREV CLOSE
12.32
HIGH
13.35
LOW
12.43
VOLUME
143.76K
TURNOVER
--
52 WEEK HIGH
25.19
52 WEEK LOW
7.26
MARKET CAP
548.52M
P/E (TTM)
-9.2275
1D
5D
1M
3M
1Y
5Y
1D
TD Cowen Sticks to Its Buy Rating for Sionna Therapeutics, Inc. (SION)
TipRanks · 7h ago
Sionna Therapeutics GAAP EPS of -$0.62 misses by $0.16
Seeking Alpha · 14h ago
Weekly Report: what happened at SION last week (0505-0509)?
Weekly Report · 15h ago
Sionna Therapeutics reports Q1 EPS (62c), consensus (45c)
TipRanks · 16h ago
Sionna Therapeutics Q1 EPS $(0.62) Misses $(0.44) Estimate
Benzinga · 16h ago
SIONNA THERAPEUTICS: PHASE 1 TOPLINE DATA FOR NBD1 STABILIZERS SION-719 & SION-451 EXPECTED THIS QUARTER
Reuters · 16h ago
*Sionna Therapeutics 1Q Research and Development Expenses $13.7M >SION
Dow Jones · 16h ago
Press Release: Sionna Therapeutics Reports First Quarter 2025 Financial Results
Dow Jones · 16h ago
More
About SION
More
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Recently
Symbol
Price
%Change

Webull offers Sionna Therapeutics, Inc. stock information, including NASDAQ: SION real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SION stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SION stock methods without spending real money on the virtual paper trading platform.